Hot Features
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb t... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.055 | 0.055 | 0.05 | 6725 | 0.05433084 | CS |
| 4 | -0.005 | -8.33333333333 | 0.06 | 0.06 | 0.04 | 33213 | 0.05404465 | CS |
| 12 | -0.02 | -26.6666666667 | 0.075 | 0.075 | 0.04 | 34470 | 0.06185872 | CS |
| 26 | -0.04 | -42.1052631579 | 0.095 | 0.11 | 0.04 | 59688 | 0.08232012 | CS |
| 52 | -0.065 | -54.1666666667 | 0.12 | 0.16 | 0.04 | 116486 | 0.09576454 | CS |
| 156 | -0.065 | -54.1666666667 | 0.12 | 0.425 | 0.035 | 142318 | 0.12884504 | CS |
| 260 | -0.205 | -78.8461538462 | 0.26 | 0.425 | 0.035 | 114977 | 0.1537245 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.